Loading the SOTA2 catalog…
BGE-102
potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases
What is BGE-102?
potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases
Product typeDrug Discovery & Biotech
Pricing ·
Deployment
APINot available
What teams use BGE-102 for
treat cardiometabolic disease
target biology of human aging
develop therapies for obesity
develop therapies for cardiovascular risk and retinal diseases
identify molecular mediators of aging and disease
develop therapeutic product candidates for metabolic diseases
address key pathways involved in metabolic aging
find pathways impacting human lifespan and healthspan
target diseases of metabolic aging
develop novel and known biology translational drug targets
capture healthspan trajectories from healthy individuals
use unbiased approach to identify translational drug targets
use longitudinal omics coupled with serial functional assessments
use data-first approach to metabolic aging
use discovery and development expertise with tech-forward approach
use in-house translational aging core in naturally aged mice
address fundamental questions about human aging: who lives long, who lives well, and why?
Integrations and access
Platforms, integrations, and language support vary by plan and region. Confirm final requirements with the vendor.
Platforms
IntegrationsAPI and webhooks
Languages
Support
What reviewers say
Community reviewsReviews are owned and editable by their authors.
Sign in to reviewLoading community reviews…
Enterprise readiness
Compliance claims are normalized from current vendor documentation and independently reviewed by SOTA2.
Data retention:
Benchmarks and comparisons
Independent benchmarksStructured task results are being verified.
Side-by-side comparisonsComparison workspaces will be available in a later release.
